Morning of April 18th，By Shaanxi Pharmaceutical Group、Special lecture on “‘4+7’ centralized drug procurement with volume and consistency evaluation of generic drugs” jointly organized by Shaanxi Biomedical My stake betting appIndustry-University-Research Innovation Alliance，Convened in the conference room on the third floor of the group。Group Leader、Mid-level cadres、Operation and management personnel of group-owned enterprises and alliance member unit Shaanxi Buchang Pharmaceutical、Wanlong Pharmaceutical、Century Shengkang Pharmaceutical、Xintong Drug、More than 180 people from more than 60 well-known pharmaceutical companies in the province, including Panlong Pharmaceutical, attended the meeting。Shan Zhifeng, chief pharmacist of the group, presided over the meeting。

The meeting invited the vice president of China Chemical and Pharmaceutical Industry Association、Director of the Policy and Regulations Committee、Dr. Zhang Ziran, director of the Special Committee for Listed Companies, talks about "In-depth analysis of the impact and countermeasures of "4+7" centralized drug procurement in volume on pharmaceutical companies。Deputy Director Hou Hongjun of the Drug Registration Office of the Provincial Food and Drug Administration stake online sports bettinggave a policy interpretation on "Enterprises Carry out Consistency Evaluation of Innovative Drugs and Generic Drugs"。

Dr. Zhang fromPolicy background of “4+7” centralized drug procurement in large quantities、Impact on pharmaceutical companies、Company response measures and future development trends are analyzed and interpreted from four aspects。He pointed out，“4+7” volume-based centralized procurement is a major measure taken by the government to promote the national health project，Significantly reduced drug prices，Enterprises speed up consistency evaluation，Increase variety reserves，Increase investment in innovation, etc.，Only in order to stand out in the fierce industry competition。

Deputy Director Hou Hongjun gave an in-depth explanation of the importance of innovative drug research and consistency evaluation of generic drugs to the future development of enterprises from a macro perspective，Through a large amount of industry information and case analysis，Explanation that enterprises should speed up the pace Stake Sports Bettingof research on consistency evaluation of generic drugs，Get volume purchasing as soon as possible"Ticket"，Continuously explore the potential value of old varieties，In order to adapt to future industry development，Realize innovation and upgrade。

Finally, Chief Pharmacist Shan Zhifeng concluded and pointed out,“4+7” drug quantity procurement and consistency evaluation，It has brought development opportunities to some enterprises，At the same time, some companies are facing challenges，Enterprises can only proactively respond to changes in industry policies，Accelerate research on innovation and consistency evaluation of generic drugs，In order to adapt to the changing new situation，Maintain long-term development。